Mitroflow with PRT

mitroflow_det.jpeg

Hemodynamics, durability and ease of implant in one valve

Excellent Hemodynamic Performance

  • Maximized flow area
  • Wide opening
  • Synchronous leaflet action
  • Uniform mechanical behavior
  • Optimized hemodynamic performance

Ease and Versatility of Implant

  • Small, streamlined sewing ring
  • Low valve profile
  • Valve versatility

Proven Clinical Results

  • Unique design since 1982
  • Excellent long-term clinical outcomes

PRT Treatment

  • PRT is aimed at mitigating calcification and further improvement of its exceptional performance

This product is not available for sale or distribution in the USA. For further information on product availability, please contact your local representative

Features

 


PRODUCT SIZE(mm)

Mitroflow with PRT

 

19


21


23


25


27


 

ACCESSORIES DESCRIPTION CODE

Bendable dual-ended sizers

19-21 mm
23-25 mm
27-29 mm ICV 1189
Aortic Handle AH-11

 

Evidence

Mitroflow long-term results

ISTHMUS investigators. The Italian study on the Mitroflow postoperative results (ISTHMUS): a 20-year, multicentre evaluation of Mitroflow pericardial bioprosthesis. Eur J Cardiothorac Surg. 2011 Jan;39(1):18-26

Numbers of patients 1591
Implant time frame Nov 1988 - June 2008
Mean Age(yrs) 75.3 ± 6.8
Total patient(yrs) 7.447
Mean Follow up (yrs) 61.9 months

“Our echocardiographic findings at discharge and at follow-up, obtained at rest, were consistent with satisfactory hemodynamic properties of the Mitroflow pericardial valve, particularly in small sizes, and confirmed excellent and constant hemodynamic performances in the majority of the patients also at long term, in accordance to the findings of Yankah and colleagues”

 


Clinical results


 

 

 


 

Conclusions

“This study indicates that the Mitroflow pericardial valve provides favorable postoperative results at long term in terms of valve durability, valve-related events and patient clinical conditions. Furthermore, good hemodynamic performance can be expected postoperatively, even in the presence of small prosthetic sizes, therefore representing, in our opinion, an extremely valuable bioprosthesis in case of planned aortic valve replacement with a tissue valve, particularly for patients older than 70 years or in the presence of a small aortic annulus.”

Yankah CA, Pasic M, Musci M et al. Aortic valve replacement with the Mitroflow pericardial bioprosthesis: durability results up to 21 years. J Thorac Cardiovasc Surg. 2008 Sep;136(3):688-96.

N° of patients 1513
Implant time frame March 1986 - Apr 2007
Mean Age (yrs) 73.2 ± 0.22 yrs
Average Follow up 4.07 ± 0.12 yrs
Total patient years 6163.5

 

Hemodynamic results

 


 

Clinical results 


 

 

 


 

Conclusions

“The Mitroflow pericardial bioprosthesis exhibits very low pressure gradients combined with easy implantability. After two decades of follow-up, the Mitroflow pericardial aortic valve continues to be a valve of choice with a predictable low rate of valve-related events, particularly for patients over the age of 65 -70 and others with comorbidities.”

 


Excellent long-term clinical outcomes

  • ISTHMUS Investigators, The Italian study on the Mitroflow postoperative results (ISTHMUS): a 20-year, multicentre evaluation of Mitroflow pericardial bioprosthesis. Eur J Cardiothorac Surg, 2011. 39(1): p. 18-26; discussion 26. Click here
  • Asch, F.M., et al., Mitroflow aortic bioprosthesis 5-year follow-up: North American prospective multicenter study. Ann Thorac Surg, 2012. 94(4): p. 1198-203. Click here
  • Conte, J., et al., A North American, prospective, multicenter assessment of the Mitroflow aortic pericardial prosthesis. Ann Thorac Surg, 2010. 90(1): p. 144-152.e1-3. Click here
  • Jamieson WR,et. al., Mitroflow aortic pericardial bioprosthesis--clinical performance. Eur J Cardiothorac Surg. 2009 Nov;36(5):818-24. doi: 10.1016/j.ejcts.2009.05.020. Epub 2009 Aug 22. Click here
  • Joshi, V., et al., Early prosthetic valve degeneration with Mitroflow aortic valves: determination of incidence and risk factors. Interact Cardiovasc Thorac Surg, 2014. 19(1): p. 36-40. Click here
  • Sjogren, J., et al., Long-term outcome of the MitroFlow pericardial bioprosthesis in the elderly after aortic valve replacement. J Heart Valve Dis, 2006. 15(2): p. 197-202. Click here
  • Wilbring, M., et al., Isolated aortic valve replacement in patients with small aortic annulus-a high-risk group on long-term follow-up. Thorac Cardiovasc Surg, 2013. 61(5): p. 379-85. Click here
  • Yankah, C.A., et al., Aortic valve replacement with the Mitroflow pericardial bioprosthesis: durability results up to 21 years. J Thorac Cardiovasc Surg, 2008. 136(3): p. 688-96. Click here

Download Area

  • Sorin Magnetic Resonance Document download 153.61 kB application/pdf

This product may not be for sale in your country or your area. For further information on product availability, please contact your local representative

Version unknown | Revision 68868 | Status unknown | SessionId 8C0E407309581573A037B6973B76D879.jvm1